No bio added yet
No link addedCatalysts https://mfn.se/all/a/bio-stock/bioval-analysis-of-alzinovas-alz-101-rnpv-of-sek-7-1b Catalysts Alzinova appears undervalued compared to the recent BioVal analysis, which values ALZ-101 at around SEK 7.1bn rNPV , far above the current market valuation. ALZ-101 has shown positive Phase 1b safety and immune-response data, and the company is preparing for Phase 2.Read more